دورية أكاديمية
Fitness-Dependent, Mild Mutagenic Activity of Sofosbuvir for Hepatitis C Virus.
| العنوان: | Fitness-Dependent, Mild Mutagenic Activity of Sofosbuvir for Hepatitis C Virus. |
|---|---|
| المؤلفون: | Martínez-González B; Department of Molecular and Cell Biology, Centro Nacional de Biotecnología (CNB-CSIC), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.; Department of Clinical Microbiology, IIS-Fundación Jiménez Díaz, Madrid, Spain., Gallego I; Centro de Biología Molecular 'Severo Ochoa' (CSIC-UAM), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain., Gregori J; Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain., Soria ME; Department of Molecular and Cell Biology, Centro Nacional de Biotecnología (CNB-CSIC), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.; Department of Clinical Microbiology, IIS-Fundación Jiménez Díaz, Madrid, Spain., Somovilla P; Centro de Biología Molecular 'Severo Ochoa' (CSIC-UAM), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.; Departamento de Biología Molecular, Universidad Autónoma de Madrid, Madrid, Spain., de Ávila AI; Centro de Biología Molecular 'Severo Ochoa' (CSIC-UAM), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain., García-Crespo C; Centro de Biología Molecular 'Severo Ochoa' (CSIC-UAM), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain., Durán-Pastor A; Department of Molecular and Cell Biology, Centro Nacional de Biotecnología (CNB-CSIC), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain., Briones C; Centro de Astrobiología (CAB, CSIC-INTA), Madrid, Spain., Gómez J; Instituto de Parasitología y Biomedicina 'López-Neyra' (CSIC), Parque Tecnológico Ciencias de la Salud, Granada, Spain., Quer J; Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) del Instituto de Salud Carlos III, Madrid, Spain.; Biochemistry and Molecular Biology Department, Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain., Domingo E; Centro de Biología Molecular 'Severo Ochoa' (CSIC-UAM), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain., Perales C; Department of Molecular and Cell Biology, Centro Nacional de Biotecnología (CNB-CSIC), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.; Department of Clinical Microbiology, IIS-Fundación Jiménez Díaz, Madrid, Spain. |
| المصدر: | Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2023 Jul 18; Vol. 67 (7), pp. e0039423. Date of Electronic Publication: 2023 Jun 27. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 0315061 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-6596 (Electronic) Linking ISSN: 00664804 NLM ISO Abbreviation: Antimicrob Agents Chemother Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Washington, American Society for Microbiology |
| مواضيع طبية MeSH: | Hepatitis C*/drug therapy , Hepatitis C, Chronic*/drug therapy, Humans ; Sofosbuvir/pharmacology ; Sofosbuvir/therapeutic use ; Hepacivirus/genetics ; Mutagens/pharmacology ; Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; Genotype ; Ribavirin/therapeutic use ; Treatment Outcome ; Drug Therapy, Combination |
| مستخلص: | The concept of a mild mutagen was coined to describe a minor mutagenic activity exhibited by some nucleoside analogues that potentiated their efficacy as antiretroviral agents. In the present study, we report the mild mutagen activity of sofosbuvir (SOF) for hepatitis C virus (HCV). Serial passages of HCV in human hepatoma cells, in the presence of SOF at a concentration well below its cytotoxic concentration 50 (CC |
| References: | PLoS One. 2018 Oct 3;13(10):e0204877. (PMID: 30281674) Genome Biol Evol. 2017 May 1;9(5):1212-1228. (PMID: 28460010) Future Med Chem. 2019 Jul;11(13):1645-1657. (PMID: 31469331) Virology. 2016 Jun;493:227-37. (PMID: 27060566) Science. 2005 Jul 22;309(5734):623-6. (PMID: 15947137) J Mol Med (Berl). 2002 Feb;80(2):86-95. (PMID: 11907645) PLoS Med. 2018 Mar 27;15(3):e1002535. (PMID: 29584730) J Virol. 2017 Apr 28;91(10):. (PMID: 28275194) Antivir Ther. 2017;22(7):587-597. (PMID: 28248189) Nat Biotechnol. 2010 Feb;28(2):167-71. (PMID: 20118917) J Virol. 2014 Oct;88(20):12098-111. (PMID: 25122776) Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4448-52. (PMID: 15767582) J Virol. 2000 Sep;74(18):8316-23. (PMID: 10954530) Virology. 2018 Oct;523:100-109. (PMID: 30107298) Viruses. 2022 Apr 18;14(4):. (PMID: 35458571) Annu Rev Microbiol. 2004;58:183-205. (PMID: 15487935) BMC Infect Dis. 2018 Sep 3;18(1):446. (PMID: 30176817) J Virol. 2013 Jul;87(13):7593-607. (PMID: 23637397) Antimicrob Agents Chemother. 2012 Jun;56(6):3359-68. (PMID: 22430955) Bioorg Med Chem. 2013 Nov 15;21(22):7222-8. (PMID: 24120088) Curr Top Microbiol Immunol. 2023;439:1-94. (PMID: 36592242) Sci Rep. 2017 Jan 18;7:40920. (PMID: 28098253) J Biol Chem. 2007 Oct 12;282(41):29812-20. (PMID: 17698842) Evolution. 1990 Nov;44(7):1725-1737. (PMID: 28567811) Trends Microbiol. 2013 Feb;21(2):56-62. (PMID: 23195922) Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1492-7. (PMID: 9990051) Virus Res. 2017 Jul 15;239:115-125. (PMID: 28040474) J Theor Biol. 1989 Apr 20;137(4):375-95. (PMID: 2626057) Front Mol Biosci. 2022 Jan 25;8:823253. (PMID: 35145998) Antiviral Res. 2020 Feb;174:104694. (PMID: 31857134) Biology (Basel). 2022 Apr 30;11(5):. (PMID: 35625421) Antimicrob Agents Chemother. 2016 May 23;60(6):3786-93. (PMID: 27067341) Bioinformatics. 2014 Apr 15;30(8):1104-1111. (PMID: 24389655) Hepatology. 2008 Dec;48(6):1843-50. (PMID: 19003912) J Med Chem. 2022 Nov 10;65(21):14261-14275. (PMID: 36282210) Evolution. 2020 Dec;74(12):2549-2559. (PMID: 33047822) J Virol. 2002 Dec;76(24):13001-14. (PMID: 12438626) J Hepatol. 2020 Nov;73(5):1170-1218. (PMID: 32956768) Clin Pharmacokinet. 2015 Jul;54(7):677-90. (PMID: 25822283) Virus Res. 2005 Feb;107(2):173-81. (PMID: 15649563) Antimicrob Agents Chemother. 2014 Jul;58(7):3636-45. (PMID: 24733478) Br J Clin Pharmacol. 2017 Feb;83(2):269-293. (PMID: 27530469) Curr Opin Virol. 2014 Oct;8:10-5. (PMID: 24846716) Elife. 2014 Oct 21;3:e03679. (PMID: 25333492) J Virol. 2013 Apr;87(7):3741-51. (PMID: 23325689) Antimicrob Agents Chemother. 2018 Apr 26;62(5):. (PMID: 29439971) PLoS Pathog. 2010 Aug 26;6(8):e1001072. (PMID: 20865120) J Med Chem. 2010 Oct 14;53(19):7202-18. (PMID: 20845908) Nat Med. 2000 Dec;6(12):1375-9. (PMID: 11100123) J Chromatogr Sci. 2016 Oct 17;54(9):1631-1640. (PMID: 27436268) Viruses. 2021 Apr 03;13(4):. (PMID: 33916702) PLoS One. 2016 Oct 18;11(10):e0164691. (PMID: 27755573) Antimicrob Agents Chemother. 2002 Apr;46(4):977-81. (PMID: 11897578) J Mol Biol. 2008 Oct 10;382(3):652-66. (PMID: 18662697) Hepatology. 2015 Nov;62(5):1623-32. (PMID: 26095927) Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6895-900. (PMID: 11371613) Virology. 2016 Jul;494:257-66. (PMID: 27136067) J Virol. 2020 Feb 28;94(6):. (PMID: 31852791) |
| فهرسة مساهمة: | Keywords: antiviral agent; lethal defection; ultradeep sequencing; viral fitness; viral quasispecies |
| المشرفين على المادة: | WJ6CA3ZU8B (Sofosbuvir) 0 (Mutagens) 0 (Antiviral Agents) 49717AWG6K (Ribavirin) |
| تواريخ الأحداث: | Date Created: 20230627 Date Completed: 20230717 Latest Revision: 20231228 |
| رمز التحديث: | 20231228 |
| مُعرف محوري في PubMed: | PMC10353389 |
| DOI: | 10.1128/aac.00394-23 |
| PMID: | 37367486 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1098-6596 |
|---|---|
| DOI: | 10.1128/aac.00394-23 |